Roflumilast foam 0.3% sNDA submitted to treat scalp and body psoriasis in patients 12 years and up

Published Date: 25 Jul 2024

If approved, roflumilast foam 0.3% for scalp and body psoriasis treatment would add to the multiple already-approved roflumilast indications.

Read Full News

Latest News


News All Time

HTTP error: 503HTTP error: 503 HTTP error: 503 HTTP error: 503 HTTP error: 503HTTP error: 503HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

2.

EVP Beats Cisplatin for Resectable MIBC

3.

For elderly, unfit patients, the all-oral AML regimen shows promise.

4.

Study sets benchmark for treatment of advanced cervical cancer

5.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot